

---

**Epidemiology**

---

**Abstract citation ID: jjad212.1285****P1155****Impact of COVID19 pandemic and vaccination among IBD patients: a multinational cross sectional survey**

P. Alavi Nejad Ass. Prof.<sup>1</sup>, M. Mokhtare<sup>2</sup>, F. Farsi<sup>3</sup>, M. Arshadzadeh<sup>4</sup>, S. Shetty<sup>5</sup>, O. Eslami<sup>6</sup>, M. Arefi<sup>7</sup>, M.H. Emarā<sup>8</sup>, E. Abdelsameea<sup>9,1</sup>, J. Rezaei<sup>10</sup>, S.M.A. Alavi<sup>10</sup>, Q.T. Tran<sup>11</sup>, R. Salma<sup>12</sup>, A. Parsi<sup>10</sup>, M.H. Ahmed<sup>13</sup>, A. Monged<sup>14</sup>, A. Quadri<sup>15</sup>, A. Jawad<sup>16</sup>, A.U. Rehman<sup>17</sup>, S.H. Lee<sup>18</sup>, N.S. Behl<sup>19</sup>, E. Ghoneem<sup>20</sup>

<sup>1</sup>Ahvaz Jundishapur university of medical sciences, Alimentary Tract research Center- Ahvaz Imam Hospital, Copenhagen, Denmark <sup>2</sup>Iran university of medical sciences, GI Department, Tehran, Iran- Islamic Republic Of <sup>3</sup>Iran University of medical sciences, Minimally Invasive Surgery Research Center, Tehran, Iran- Islamic Republic Of <sup>4</sup>Tehran University of medical Sciences, Faculty of medicine, Tehran, Iran- Islamic Republic Of <sup>5</sup>Kasturba Medical College- Manipal University, Department of gastroenterology and hepatology, Kasturba, India <sup>6</sup>Kerman University of Medical Sciences, Clinical research Development Unit- Afzalipour Hospital, Kerman, Iran- Islamic Republic Of <sup>7</sup>Tehran University of Medical Sciences, Toxicology Center of Baharloo Hospital, Tehran, Iran- Islamic Republic Of <sup>8</sup>Kaflelsheikh University, Faculty of Medicine- Department of Hepatology- Gastroenterology and Infectious diseases, Kafrelelsheikh, Egypt <sup>9</sup>Menoufia University, National Liver Institute, Menoufia, Egypt <sup>10</sup>Ahvaz Jundishapur University of Medical sciences, Alimentary Tract research Center, Ahvaz, Iran- Islamic Republic Of <sup>11</sup>Hue University, University of Medicine and pharmacy, Hue, Vietnam <sup>12</sup>Zagazig University, Tropical Medicine Department, Kairo, Egypt <sup>13</sup>Kafrelelsheikh University, Gastroenterology and Infectious Diseases Department, Mansoura, Egypt <sup>14</sup>Royal College of Surgeons of Ireland Hospitals, GI Department, Dublin, Ireland <sup>15</sup>Dr VRK Woman's Medical College, internal medicine hospital, Telangana, India <sup>16</sup>Dr VRK womens Medical College, internal medicine department, Hyderabad, India <sup>17</sup>Faisalabad Medical University, internal medicine department, Faisalabad, Pakistan <sup>18</sup>Seoul National university Hospital, department of internal medicine and liver research institute, Seoul, Korea- Republic Of <sup>19</sup>Fortis Hospitals, Institute of gastro and liver Sciences, Hyderabad, India <sup>20</sup>Mansoura University, Gastroenterology and Hepatology Department, Mansoura, Egypt

**Background:** The aim of current study is to evaluate impact of COVID19 pandemic and vaccination against it on the course and symptoms of IBD.

**Methods:** During a six months' period, all of the IBD cases who attend in outpatient clinics of nine referral centers in 6 countries include and request to fill a questionnaire about their demographic characters and pattern of IBD, any history of involvement with COVID19 and their vaccination history.

**Results:** overall 812 cases from 16 countries included (52.4% male) with average age of 36.8 y (range 7 – 76). 68.5% of participants diagnosed as UC and 29.5% as CD. 80% of participants have vaccinated against COVID19 (average 2.3 times, range 1 – 5). Among those who vaccinated (group A) 31.6% experienced side effects and complication without any mortality. The most common complications of vaccination include fever (24%), fatigue (20.1%) and anorexia 8.6%. The most common reasons for vaccination refusal (group B) were fear of vaccine complication (55.5%), no believe in vaccine protection (29.6%) and fear of immunocompromised condition (17.9%). In group A overall 61% of participants involved with COVID 19 (36.2% after vaccination) in comparison with 48.1% in group B (P = 0.0052). Most of the involvements in both groups were not sever and just a minority of patients admitted to hospital (10% in group A and 6.4% in group B). Following COVID involvement, 45.1% of cases suffered with GI symptoms (mostly diarrhea (72.5%) and abdominal pain (64.5%)). In group A, 37.3% of involvements have happened before vaccination.

**Conclusion:** Vaccination against COVID19 is safe and effective among IBD patients and following vaccination, most of complications are minor and negligible. In case of COVID involvement, it would not be serious and there is no need to hold the medications. Among IBD patients, the most common reason for vaccination refusal is fear of vaccine side effect.